Clinical Trials Search
Clinical Trial 18527
Cancer Type: Multiple
Interventions:BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Not Applicable; Yervoy (Ipilimumab)
Study Type: Treatment
Phase of Study: Phase I/II
Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherpay and Nivolumab Combination Therapy in Subjects with Virus-Positive and Virus-Negative Solid Tumors
The purpose of this study to investigate the safety and efficacy of using nivolumab to treat participants who have virus-associated tumors. Certain viruses that infect human cells have been known to play a role in tumor formation and growth. This study will investigate the effects of the study drug nivolumab in participants who have the following types of viral-associated tumors: Gastric Cancer, nasopharyngeal carcinoma , cervical cancer, vaginal cancer, vulvar cancer, squamous cell carcinoma of the head and neck, and Merkel Cell Carcinoma.
In the neoadjuvant cohort, to investigate the safety and tolerability of neoadjuvant nivolumab administration in the applicable tumor types. In the metastatic/recurrent cohort, to evaluate the investigator-assessed objective response rate (ORR) of nivolumab monotherapy in subjects with the applicable diseases.